Chemically Modified Tetracyclines Chemically Modified Tetracyclines

The use of chemotherapeutic agents or drugs specifically designed to treat periodontal diseases is emerging to aid in this risk assessment and reduction strategy. They include locally applied and systemically delivered antimicrobials and host modulatory thera - pies. Tetracyclines are a group of antibiotics produced naturally from certain species of Streptomyces or derived semisynthetically. Their advantages were broad-spectrum activ ity, better tolerated, and less toxic to some individuals. Further modifications of these natural products by means of synthetic reactions and reagents led to the production of the clinically used antibiotic tetracycline compounds—minocycline, doxycycline, and methacycline. Tetracyclines are now recognized to have non-antimicrobial properties that may also be therapeutically advantageous. They have anti-inflammatory properties, particularly in the treatment of certain skin diseases. One important aspect is their abil ity to inhibit host collagenolytic enzymes, an effect that inhibits the connective tissue degradation and thus preventing bone resorption. To identify the site of the anticollage nase property, Golub and co-workers in 1991 synthesized 10 different analogs of tetra - cyclines known as chemically modified tetracyclines (CMTs 1-10). All 10 analogs lacked antimicrobial efficacy and inhibited collagenase activity, but only 1 did not. Though not approved for human use by the FDA, preliminary studies using CMT-3 are being inves tigated on humans with cancer.


Introduction and background
Host modulation with chemotherapeutic therapy or drugs is a new adjunctive therapeutic option for the management of periodontal diseases. The concept of host modulation was introduced by Williams and Golub et al. and then expanded on by many scholars. Various studies have indicated that host responses believed to be involved in pathogenesis of periodontal diseases may be efficacious in slowing progression of periodontitis. For the management of periodontal diseases, conventional approaches were initially mechanical in nature, as reviewed in the historical section, that is, surgery as well as scaling and root planning. New adjunctive approaches involve modulation of the host response. It has been recognized that genetic, environmental (e.g., tobacco use), and acquired risk factors (e.g., systemic disease) can increase a patient's susceptibility to developing periodontitis. Some of these risk factors can be modified to reduce a patient's susceptibility.
Risk assessment and therapy may include smoking cessation, improved control of diabetes, nutritional supplementation, improved oral hygiene, changes in medication, stress management, and more frequent dental visits.
The use of chemotherapeutic agents or drugs specifically designed to treat periodontal diseases is emerging to aid in this risk assessment and reduction strategy. They include locally applied and systemically delivered antimicrobials and host modulatory therapies which can be used to reduce excessive levels of enzymes, cytokines, and prostanoids as well as to modulate osteoclast and osteoblast function. Golub and colleagues discussed "host modulation with tetracyclines and their chemically modified analogs." When considering the imbalance in destructive or pro-inflammatory mediators versus protective or anti-inflammatory mediators in the diseased state, physicians should contemplate the use of pharmacological agents or host modulatory therapy.
Tetracyclines are a group of antibiotics produced naturally from certain species of Streptomyces or derived semisynthetically. Chlortetracycline (Figure 1) is the first tetracycline to be fully characterized both chemically and clinically. Their advantages were broad-spectrum activity, better tolerated, and less toxic to some individuals. Further modifications of these natural products by means of synthetic reactions and reagents led to the production of the clinically used antibiotic tetracycline compounds-minocycline, doxycycline, and methacycline.

Advantages of tetracyclines in periodontitis
Chemically modified tetracycline plays an important role in suppressing the concentration of Gram-negative microorganisms in the subgingival plaque. Concentration in the (GCF) was 5-10 times greater than in serum. Tetracyclines are now recognized to have nonantimicrobial properties that may also be therapeutically advantageous. An ability to promote fibroblast and connective tissue attachment to tooth & other surfaces (Figure 2), which is relevant to periodontal regeneration. They have anti-inflammatory properties, particularly in the treatment of certain skin diseases like rosacea, dermatitis herpetiformis and epidermolysis bullosa, disorders that are not thought to have a bacterial etiology and their ability to inhibit host collagenolytic enzymes, an effect that inhibits the connective tissue degradation, including bone resorption [1].

Matrix metalloproteinases (MMPs)
These are a family of enzymes capable of degrading connective tissue matrix. These enzymes are secreted in latent form by fibroblasts, keratinocytes, macrophages and polymorphoneutrophils. 1. "Pre" region to target for secretion 2. "Pro" region to maintain latency 3. Catalytic region that contains the active zinc-binding site 4. Proline-rich hinge region, which acts as a zinc-binding site The majority of MMPs have additional domains, such as hemopexin region or fibronectin-like region, which play a role in recognition and in inhibitor binding.

Host modulatory therapy
It is a treatment concept that aims to reduce tissue destruction and stabilize or even regenerate the periodontium by modifying or downregulating destructive aspects of host response and upregulating protective or regenerative responses [3,4].
Various host modulatory agents proposed to block pathways responsible for periodontal tissue destruction are:

Chemically modified tetracyclines (CMTs)
The unexpected ability of tetracyclines to inhibit the breakdown of the connective tissue and bone by a nonantimicrobial mechanism was first reported over six decades. Based on the thoroughly explored chemistry of tetracyclines, a number of tetracycline analogs can be synthesized with side-chain deletions or, in some cases, moieties added to the parent tetracycline molecule. Golub and co-workers (1983,1987) [5] made the observation that collagenase activity was inhibited by tetracycline.
Their study showed that: in severe hypoglycemic rats, there was a shift to Gram-negative microflora in subgingival plaque with more of endotoxin penetration into subepithelial connective tissue leading to stimulation of host cells.

The diabetic rat model
Golub [5] and co-workers modified their experimental diabetes protocol using tetracycline therapy and germ-free rats to determine whether the Gram-negative microflora increased collagenase levels (Figure 5).
As a result of these initial studies, Golub et al. proposed: 1. Collagenase action was inhibited by tetracycline.

2.
This property of tetracycline can be useful not only for periodontal disease but also for rheumatoid and osteoarthritis (as well as several cutaneous and other diseases) that involve collagen destruction.
Tetracyclines are known to inhibit collagenase and some other, but not all, matrix metalloproteinases or MMPs from a variety of cells: Figure 5. The diabetic rat model.
• During inflammation, collagenolytic activity will be reduced by the use of these drugs but not the collagen turnover.
To identify the site of the anti-collagenase property, Golub and co-workers (1991) [5] synthesized 10 different analogs of tetracyclines known as chemically modified tetracyclines (CMTs 1-10). All 10 analogs lacked antimicrobial efficacy and inhibited collagenase activity, but only 1 did not.

Structure of CMT
This modification did not reduce the ability of drug to block the activity of collagenases from a number of tissue sources (PMNs, gingiva, osteoblasts, synovial tissue, lung cancer cells) or Chemically Modified Tetracyclines http://dx.doi.org/10.5772/intechopen.79724 its ability to inhibit bone resorption [8] (Figure 7). Thus, it was concluded that the C-4 moiety had no role in anti-collagenase action of the drug.
When changes were made at C-11 and C-12 position by converting tetracycline to the pyrazole derivative or CMT-5, the collagenase inhibitory activity was lost.
These carbon groups are thought to be the sites for cation binding at physiologic pH 48, and all collagenases are known to require the cations, calcium and zinc, for their hydrolytic activity.

Mechanism of action of CMTs
a. CMTs bind metal ions, particularly Ca2+ and Zn2+, which are required by enzymes for their normal activity [9] (Figure 8).
b. Inhibition of pro-MMPs.
Other mechanisms that have been proposed include: • Retards cytokine production. • Inhibition of protein glycation.
• Inhibit secretion of other collagenolytic enzymes like lysosomal cathepsin.
• Modulates the osteoclast function and inhibits already active MMPs.
Tetracyclines affect several parameters of osteoclast function (Figure 9).

Action on P. gingivalis and T. denticola
• Inhibits Arg-and Lys-gingipain activities and collagenolytic activity of P. gingivalis.
• Inhibited trypsin like activity of T. denticola.
• CMT-I inhibited serum albumin degradation by P. gingivalis and T. denticola.
• CMT's potential advantages over conventional tetracyclines: • The recent observations in rats showed that CMT-1 is absorbed after oral administration more rapidly and has a longer serum half-life than tetracycline. • Their long-term systemic administration does not result in gastrointestinal toxicity.
• Can be used for prolonged periods.

Current status of CMTs
• Though not approved for human use by the FDA, preliminary studies using CMT-3 are being investigated on humans with cancer.
• Greenwald et al. recently conducted a synergism study using CMT-1 + flurbiprofen, a standard nonsteroidal anti-inflammatory drug selected primarily because of its reported beneficial effect on bone loss in humans with adult periodontitis and the beagle dog model of periodontal disease.

Periostat
It is subantimicrobial dose of doxycycline hyclate (SDD) capsule of 20 mg prescribed for patients with chronic periodontitis twice daily for 3 months, up to a maximum of 9 months of continuous dosing [10]. Indications for periostat are patients who have not responded to nonsurgical therapy, patients with generalized recurrent sites of 5 mm or greater pocket depth that bleed on probing, and patients with mild to moderate chronic periodontitis and a high susceptibility to rapid periodontal disease progression. It is the only FDA-approved systemically administered HMT indicated in the treatment of periodontitis [11]. Most patients will have small (i.e., less than 1 mm) additive effect on pocket depth reduction when this systemic approach is added to scaling and root planning. Modulation of host response may be valuable in enhancing effects of antimicrobial agents, such as doxycycline, which are locally released and in periodontitis treatment, especially in smokers.

Mechanism
The rationale for using SDD is based on the concept of host modulation; that is, it downregulates the activity of destructive responses such as MMP activity and upregulates protective responses as it promotes osteoblastic activity leading to new bone formation by upregulating collagen production.

Indications
a. Indicated in the management of chronic periodontitis b. Can be used in patients with Ag periodontitis who are treated nonsurgically c. Can also be used as an adjunct to periodontal surgery d. May also be beneficial in cases that are refractory to treatment, as well as in patients with risk factors such as smoking or diabetes, in whom the treatment response might be limited

Contraindications
SDD should not be used in conditions such as gingivitis and periodontal abscess or when an antibiotic is indicated. The other contraindication of its use is in allergy to tetracycline. Patients taking oral contraceptives may have reduced protection from pregnancy with this therapy.
Host modulation therapy is an emerging treatment concept and can be used in susceptible, high-risk patients in whom a prolonged and excessive host response to microorganisms promotes activity of MMPs and osteoclast. Clinical trials have demonstrated a clear treatment benefit when it is used in combination with phase I therapy. The further development of these agents will help clinicians to treat specific aspects of periodontal diseases by reducing inflammation and inhibiting destructive processes in tissues, which will result in enhanced periodontal stability after conventional periodontal treatment such as scaling root planning (SRP) and surgery.
Ramamurthy et al. (2002) tested doxycycline and five different CMTs to prevent MMPdependent periodontal tissue breakdown in an adult rat model. CMTs were administered orally at conc. 2 mg/day for 7 days, and gingival biopsies were taken to assess cytokines TNF, IL-1, and MMP-2 and MMP-9. All tetracycline inhibited periodontal breakdown in the following order of efficacy: CMT, 8 > 1 > 3 > doxy >4 > 7.
Long-term (i.e., 9-18 months) administration of SDD does not result in emergence of resistant organism or alteration of subgingival microflora. Various long term studies have been conducted.
Doxycycline 20 mg bid was used in 51 patients with active periodontitis based on pocket depth and increased collagenase at multiple exams showed no clinical attachment loss over 36 months.
Twenty subjects ≤ 45 year old patients with severe generalized periodontitis patients and showing >30% of sites with CAL ≥ 5 mm were given subantimicrobial dose of doxycycline for 6 months. The result showed less clinical attachment loss, probing depth. Gingival index and bleeding on probing were not significant when compared to placebo.
Doxy 20-mg bid for month along with scaling and root planning was done in 208 chronic periodontitis subjects. The patients showed improvements in clinical attachments level and probing depth ≥ 4 mm.
Used 20 mg bid SDD for 9 months + scaling and root planning in 190 adult periodontitis patients, there was a significant improvements in CAL (≥ 2 mm) PD and BOP when compared to placebo group receiving only SRP.